CORESTEM Inc Total Assets
CORESTEM Inc total assets. Based on the latest financial reports, CORESTEM Inc (166480) holds total assets worth ₩113.27 Billion KRW (≈ $76.76 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is CORESTEM Inc worth for the company's overall valuation and market capitalisation.
Total Assets of CORESTEM Inc (2014–2024)
Total assets of CORESTEM Inc from 2014 to 2024. This chart illustrates how CORESTEM Inc's total assets have evolved over time, based on quarterly financial data. See CORESTEM Inc stock price for real-time trading data and today's change.
CORESTEM Inc - Asset Composition Analysis
CORESTEM Inc Total Assets Breakdown (December 2024)
CORESTEM Inc total assets breakdown as of December 2024. CORESTEM Inc's total assets of ₩113.27 Billion consist of 13.4% current assets and 86.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.1% |
| Accounts Receivable | ₩9.73 Billion | 8.3% |
| Inventory | ₩515.89 Million | 0.4% |
| Property, Plant & Equipment | ₩90.09 Billion | 76.7% |
| Intangible Assets | ₩2.26 Billion | 1.9% |
| Goodwill | ₩3.95 Billion | 3.4% |
Asset Composition Trend (2014–2024)
This chart illustrates how CORESTEM Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of CORESTEM Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CORESTEM Inc's current assets represent 13.4% of total assets in 2024, a decrease from 43.0% in 2014.
- Cash Position: Cash and equivalents constituted 1.1% of total assets in 2024, down from 6.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 15.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 76.7% of total assets.
CORESTEM Inc Competitors by Total Assets
Key competitors of CORESTEM Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
CORESTEM Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.27 | 0.35 | 1.48 |
| Quick Ratio | 0.27 | 0.34 | 1.48 |
| Cash Ratio | 0.00 | 0.05 | 0.00 |
| Working Capital | ₩-35.73 Billion | ₩-33.95 Billion | ₩33.07 Billion |
CORESTEM Inc - Advanced Valuation Insights
This section examines the relationship between CORESTEM Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.93 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 49.5% |
| Total Assets | ₩117.46 Billion |
| Market Capitalization | $30.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values CORESTEM Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: CORESTEM Inc's assets grew by 49.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for CORESTEM Inc (2014–2024)
The table below shows the annual total assets of CORESTEM Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩117.46 Billion ≈ $79.60 Million |
+49.45% |
| 2023-12-31 | ₩78.59 Billion ≈ $53.26 Million |
-0.03% |
| 2022-12-31 | ₩78.61 Billion ≈ $53.28 Million |
-42.37% |
| 2021-12-31 | ₩136.41 Billion ≈ $92.44 Million |
-4.52% |
| 2020-12-31 | ₩142.87 Billion ≈ $96.82 Million |
+66.81% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.04 Million |
-4.05% |
| 2018-12-31 | ₩89.26 Billion ≈ $60.49 Million |
-1.55% |
| 2017-12-31 | ₩90.67 Billion ≈ $61.45 Million |
+5.82% |
| 2016-12-31 | ₩85.69 Billion ≈ $58.07 Million |
+14.32% |
| 2015-12-31 | ₩74.95 Billion ≈ $50.80 Million |
+108.29% |
| 2014-12-31 | ₩35.99 Billion ≈ $24.39 Million |
-- |
About CORESTEM Inc
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatm… Read more